<DOC>
	<DOC>NCT02253550</DOC>
	<brief_summary>This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.</brief_summary>
	<brief_title>Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection</brief_title>
	<detailed_description>Patients with confirmed absence of cirrhosis will receive 8 weeks of treatment with Sofosbuvir and Simeprevir. Patients with confirmed presence of cirrhosis will receive 12 weeks of treatment with Sofosbuvir and Simeprevir. All patients will followed for 24 weeks post-treatment. Presence or absence of cirrhosis will be evaluated by FibroScan if no historical liver biopsy or FibroScan is available.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>HCV genotype 4 infection HCV RNA &gt;10,000 IU/mL at screening. Evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy). Any liver disease of nonHCV etiology. This includes, but is not limited to, acute hepatitis A, drug or alcoholrelated liver disease, autoimmune hepatitis, hemochromatosis, Wilson's disease, alpha1 antitrypsin deficiency, nonalcoholic steatohepatitis, primary biliary cirrhosis, or any other nonHCV liver disease considered clinically significant by the investigator. Infection/coinfection with HCV nongenotype 4. Coinfection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV1 or HIV2) (positive HIV1 or HIV2 antibodies test at screening). Coinfection with hepatitisB virus (hepatitisBsurfaceantigen [HBsAg] positive). Presence of significant comorbidities or conditions that would compromise the subject's safety and could interfere with the subject's participation for the full duration of the study in the opinion of the investigator Previously been treated with any direct acting antiHCV agent (approved or investigational) for chronic HCV infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>